

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934

September 22, 2026
Date of Report (date of earliest event reported)

Corcept Therapeutics Incorporated
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

000-50679
(Commission
File Number)

77-0487658
(I.R.S. Employer
Identification No.)

101 Redwood Shores Parkway, Redwood City, CA 94065
(Address of Principal Executive Offices) (Zip Code)

(650) 327-3270
Registrant's telephone number, including area code

Not Applicable
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.001 par value	CORT	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 22, 2026, Sean Maduck, the President of Corcept Endocrinology, notified the Board of Directors of Corcept Therapeutics Incorporated (the “Company”) of his decision to resign effective as of October 1, 2026. The Company thanks Mr. Maduck for his significant contributions to the Company and his dedication to helping patients. Mr. Maduck did not resign because of any disagreement with the Company on any matter relating to the Company’s operations, financial statements, policies or practices.

In connection with Mr. Maduck’s resignation, the Company and Mr. Maduck entered into a Consulting Services Agreement (the “Agreement”), dated as of September 22, 2026 and effective as of October 1, 2026, pursuant to which Mr. Maduck will provide consulting services to the Company’s Chief Executive Officer and executive management team. The Agreement has an initial term expiring on September 30, 2027, unless earlier terminated. Pursuant to the Agreement, Mr. Maduck will be paid a cash fee of \$57,000 per month. The Agreement further provides that during Mr. Maduck’s consulting term with the Company, Mr. Maduck’s previously awarded and currently outstanding stock options shall continue to vest according to the original vesting schedule of each such stock option. Either party may terminate the Agreement upon thirty (30) days’ prior written notice.

The foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement, a copy of which will be filed either as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ending September 30, 2026 or by amendment to this Current Report on Form 8-K and is incorporated herein by reference.

Item 7.01 Regulation FD Disclosure.

On September 23, 2026, the Company issued a press release announcing the retirement of Mr. Maduck and that Justin Gunn will succeed Mr. Maduck. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information in this Item 7.01 and the information contained in the press release attached as Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information in this Item 7.01 and the information contained in the press release attached as Exhibit 99.1 is not incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in the filing unless specifically stated so therein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Press Release of Corcept Therapeutics Incorporated, dated September 23, 2026
104.1	Cover Page Interactive Data File – the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CORCEPT THERAPEUTICS INCORPORATED

Date: September 23, 2026

By: /s/ Atabak Mokari
Name: Atabak Mokari
Title: Chief Financial Officer



CONTACT:

Investor inquiries:

ir@corcept.com

Media inquiries:

communications@corcept.comwww.corcept.com**Corcept Announces Planned Leadership Transition*****Sean Maduck to Retire; Justin Gunn Appointed President, Endocrinology***

REDWOOD CITY, Calif. – September 23, 2026 – Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the retirement of Sean Maduck, President of the company's Endocrinology division. Justin Gunn will succeed Mr. Maduck and will fully assume his new responsibilities starting October 1. Mr. Gunn will join the company's Executive Team, and will report to Joseph K. Belanoff, M.D., Corcept's Chief Executive Officer. To enable a smooth transition, Mr. Maduck will remain with the company as a senior commercial advisor.

"Few leaders have made the kind of impact Sean has made over his remarkable career. The work he has led over the past 14 years has helped and will continue to help thousands of patients living with Cushing's syndrome. I am grateful to Sean for his willingness to continue on as an advisor, particularly as we look ahead to what's next for our Endocrinology business," said Dr. Belanoff.

"In the two years since he joined Corcept, Justin has proven himself to be an outstanding commercial leader," Dr. Belanoff continued. "The medical community is beginning to understand the true prevalence and impact of Cushing's syndrome, and that means Corcept has an opportunity to reach and help many more patients. I am confident in Justin's ability to lead this important work."

Mr. Gunn joined Corcept in July 2024 as Vice President of Sales and Commercial Learning for the company's Oncology division. In his tenure at Corcept, he designed and built an entirely new field sales and training organization to support the successful launch of Lifyorli®, the company's medicine for the treatment of platinum-resistant ovarian cancer, approved in combination with nab-paclitaxel. Prior to Corcept, Mr. Gunn spent nearly 18 years with Gilead Sciences, where he led commercial sales teams in a diversity of therapeutic categories, including cardiovascular disease, respiratory disease, oncology and virology. He previously held marketing and sales roles of increasing seniority at Merck and Sepracor. Mr. Gunn holds a Bachelor of Science degree in business administration from the University of Arkansas.

About Corcept Therapeutics

For over 25 years, Corcept has focused on cortisol modulation and its potential to treat patients with a wide variety of serious disorders and has discovered more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists. Corcept is conducting advanced clinical trials in patients with hypercortisolism, solid tumors, ALS and liver disease.

Forward-Looking Statements

Statements in this press release, other than statements of historical fact, are forward-looking statements based on our current plans and expectations and are subject to risks and uncertainties that might cause our actual results to differ materially from any future results expressed or implied by such forward-looking statements.

In this press release, forward-looking statements include statements concerning: the retirement of Corcept's current President of its Endocrinology division, the appointment of his successor and the transition; Corcept's ability to help thousands of patients living with Cushing's syndrome; Sean Maduck's continued service as an advisor to Corcept; and Corcept's opportunity to reach and help many more patients.

A further description of risks and uncertainties affecting our forward-looking statements can be found in our SEC filings, which are available at our website and the SEC's website. These risks and uncertainties include, but are not limited to, those related to: our ability to operate our business; our efforts to study and develop Korlym®, Lifyorli, relacorilant, miricorilant, dazucorilant, nenocorilant and our other product candidates; those molecules' clinical attributes; regulatory approvals, mandates, oversight and other requirements imposed on our products or our business by laws, regulations or discretion of government authorities; and the scope and protective power of our intellectual property. We disclaim any intention or duty to update forward-looking statements made in this press release.